Silver Oak Advisory Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$472K Sell
394
-31
-7% -$31.7K 0.19% 47
2026
Q1
$390K Sell
425
-49
-10% -$49.7K 0.17% 49
2025
Q4
$509K Sell
474
-79
-14% -$75.5K 0.23% 42
2025
Q3
$421K Sell
553
-24
-4% -$17.9K 0.19% 47
2025
Q2
$449K Buy
577
+2
+0.3% +$1.55K 0.22% 43
2025
Q1
$474K Sell
575
-43
-7% -$35.8K 0.25% 40
2024
Q4
$477K Sell
618
-2
-0.3% -$1.66K 0.25% 38
2024
Q3
$549K Sell
620
-27
-4% -$24.3K 0.28% 38
2024
Q2
$585K Hold
647
0.32% 34
2024
Q1
$504K Sell
647
-68
-10% -$48.4K 0.28% 38
2023
Q4
$417K Sell
715
-42
-6% -$24.5K 0.24% 41
2023
Q3
$406K Sell
757
-6
-0.8% -$3.09K 0.26% 38
2023
Q2
$357K Hold
763
0.23% 37
2023
Q1
$262K Buy
763
+14
+2% +$4.72K 0.18% 45
2022
Q4
$274K Sell
749
-250
-25% -$88.6K 0.19% 41
2022
Q3
$323K Hold
999
0.24% 36
2022
Q2
$324K Sell
999
-93
-9% -$27.9K 0.23% 38
2022
Q1
$313K Hold
1,092
0.2% 42
2021
Q4
$302K Buy
+1,092
New +$277K 0.19% 42

Other funds holding LLY

Silver Oak Advisory Group's LLY Position: Q2 2026 in Review

Silver Oak Advisory Group reduced its Eli Lilly (LLY) stake by 7.3% in Q2 2026, selling an estimated $31.7K and leaving 394 shares worth $472K. The position accounts for 0.19% of the portfolio, ranked #47.

Silver Oak Advisory Group first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. The position peaked at $585K in Q2 2024. 4,634 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Silver Oak Advisory Group held 394 shares of Eli Lilly worth $472K as of Q2 2026.
  • Silver Oak Advisory Group sold 31 Eli Lilly shares in Q2 2026, an estimated $31.7K.
  • Eli Lilly made up 0.19% of Silver Oak Advisory Group's portfolio in Q2 2026, its #47 holding.
  • Silver Oak Advisory Group first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • Silver Oak Advisory Group's Eli Lilly position peaked at $585K in Q2 2024.
  • 4,634 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Silver Oak Advisory Group's 13F filing for Q2 2026, filed 3 Aug 2026.